Targeted vaccine selection in influenza vaccination;Zielgruppenspezifische Wahl des Impfstoffs bei Grippeimpfung

Deutsches Arzteblatt International

Volumn 110, Issue 47, 2013, Pages 793-798

  Wutzler, Peter ^a   Hardt, Roland ^b   Knuf, Markus ^c   Wahle, Klaus ^d  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b St Hildegardis Krankenhaus   (Germany)

^c DR HORST SCHMIDT KLINIKEN   (Germany)

^d General Practitioner   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

INFLUENZA; INFLUENZA VACCINATION; REVIEW; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; CHILD; COMORBIDITY; GERMANY; HOSPITALIZATION; HUMAN; INFANT; INFLUENZA, HUMAN; MASS IMMUNIZATION; META ANALYSIS; MIDDLE AGED; PATIENT SELECTION; PNEUMONIA, VIRAL; PRESCHOOL CHILD; PREVALENCE; RISK ASSESSMENT; SEX RATIO; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COMORBIDITY; GERMANY; HOSPITALIZATION; HUMANS; INFANT; INFLUENZA VACCINES; INFLUENZA, HUMAN; MASS VACCINATION; MIDDLE AGED; PATIENT SELECTION; PNEUMONIA, VIRAL; PREVALENCE; RISK ASSESSMENT; SEX DISTRIBUTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84890256174     PISSN: 18660452     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2013.0793     Document Type: Review

References (40)

1. Pfleiderer M: Prävention/Impfen. In: Zepp F, Ruf BR (eds.): H1N1-Update 2009: Kompendium Influenza 2009. Wiesbaden: med update 2009.
2. Belshe RB: The need for quadrivalent vaccine against seasonal influenza. Vaccine 2010;28:45-53.
3. Keitel WA, Atmar RL, Cate TR, et al.: Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med 2006:166:1121-7.
4. Couch RB, Winokur P, Brady R, et al.: Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine 2007;25:7656-63.
5. Chen WH, Cross AS, Edelman R, Sztein MB, Blackwelder WC, Pasetti MF: Antibody and Th1-type cell-mediated immune responses in elderly and young adults immunized with the standard or a high dose influenza vaccine. Vaccine 2011;29:2865-73.
6. Centers for Disease Control and Prevention: Licensure of a high-dose inactivated influenza vaccine for persons aged> or = 65 years (Fluzone High-Dose) and guidance for use - United States, 2010. MMWR Morb Mortal Wkly Rep 2010;59:485-6.
7. Heinonen S, Silvennoinen H, Lehtinen P, Vainionpää R, Ziegler T, Heikkinen T: Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: an observational cohort study. Lancet Infect Dis 2011;11:23-9.
8. Song J Y, Cheong HJ, Seo YB, et al.: Comparison of the long-term immunogenicity of two pandemic influenza A/H1N1 2009 vaccines, the MF59-adjuvanted and unadjuvanted vaccines, in adults. Clin Vaccine Immunol 2012;19:638-41.
9. Hatz C, von Sonnenburg F, Casula D, Lattanzi M, Leroux-Roels G: A randomized clinical trial to identify the optimal antigen and MF59® adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects. Vaccine 2012;30:70-7.
10. Podda A: The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001;19:2673-80.
11. Banzhoff A, Nacci P, Podda A: A new MF-59 adjuvanted vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology 2003;49:177-84.
12. Baldo V, Baldovin T, Floreani A, Carraro AM, Trivello R, Family Medicine Group of Pianiga: MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications. Vaccine 2007;25:3955-61.
13. Del Giudice G, Hilbert AK, Bugarini R, et al.: An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. V accine 2006;24:3063-5.
14. Baldo V, Baldovin T, Floreani A, Fragapane E, Trivello R: Response of influenza vaccines against heterovariant influenza virus strains in adults with chronic diseases. J Clin Immunol 2007;27:542-7.
15. Puig-Barberà J, Diez-Domingo J, Hoyos S P, Varea AB, Vidal DG: Effec - tiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age. Vaccine 2004;23:283-9.
16. Puig-Barberà J, Díez-Domingo J, Varea AB, et al.: Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisa - tions for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. Vaccine 2007;25:7313-21.
17. Mannino S, Villa M, Apolone G, et al.: Effectiveness of adjuvanted influenza vaccination in elderly subjects in Northern Italy. Am J Epidemiol 2012;176:527-33.
18. Vesikari T, Pellegrini M, Karvonen A, et al.: Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J 2009;28:563-71.
19. Vesikari T, Knuf M, Wutzler P, et al.: Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 2011;365:1406-16.
20. Huckriede A, Bungener L, Stegmann T, et al.: The virosome concept for influenza vaccines. Vaccine 2005;23:26-38.
21. Conne P, Gauthey L, Vernet P, et al.: Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients. Vaccine 1997;15:1675-9.
22. de Bruijn IA, Nauta J, Gerez L, Palache A: Virosomal influenza vaccine: a safe and effective influenza vaccine with high efficacy in elderly and subjects with low pre-vaccination antibody titers. Virus Res 2004;103:139-45.
23. Herzog C, Metcalfe IC, Schaad UB: Virosome influenza vaccine in children. Vaccine 2002;20:24-8.
24. de Bruijn IA, Nauta J, Gerez L, Palache AM: The virosomal influenza vaccine Invivac: immunogenicity and tolerability compared to an adjuvanted influenza vaccine (Fluad) in elderly subjects. Vaccine 2006;24:6629-31.
25. Baldo V, Baldovin T, Pellegrini M, et al.: Immunogenicity of three different influenza vaccines against homologous and heterologous strains in nursing home elderly residents. Clin Dev Immunol 2010:517198.
26. Salleras L, Domínguez A, Pumarola T, et al.: Effectiveness of virosomal subunit influenza vaccine in preventing influenza-related illnesses and its social and economic consequences in children aged 3-14 years: a prospective cohort study. Vaccine 2006;24:6638-42.
27. van Damme P, Arnou R, Kafeja F, et al.: Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study. BMC Infect Dis 2010;10:134.
28. Ansaldi F, Canepa P, Ceravolo A, et al.: Intanza (®) 15 mcg intradermal influenza vaccine elicits cross-reactive antibody responses against heterologous A (H3N2) influenza viruses. Vaccine 2012;30:2908-13.
29. Belshe RB, Gruber WC, Mendelman PM, et al.: Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 2000;181:1133-7.
30. Hoft D F, Babusis E, Worku S, et al.: Live and inactivated influenza vac - cines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis 2011;204:845-53.
31. Ashkenazi S, Vertruyen A, Arístegui J, et al.: CAIV-T Study Group. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006;118:2298-312.
32. Fleming DM, Crovari P, Wahn U, et al.: Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2006;25:860-9.
33. Belshe RB, Edwards KM, Vesikari, et al.: Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007;356:685-96.
34. Belshe RB, Toback SL, Yi T, Ambrose CS: Efficacy of live attenuated influenza vaccine in children 6 months to 17 years of age. Influenza Other Respi Viruses 2010;4:141-5.
35. 5. Osterholm M T, Kelley NS, Sommer A, Belongia EA: Efficacy and effec - tiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012;12:36-44.
36. Ambrose CS, Wu X, Knuf M, Wutzler P: The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: A meta-analysis of 8 randomized controlled studies. Vaccine 2012;30:886-92.
37. Belshe RB, Gruber WC, Mendelman PM, et al.: Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 2000;136:168-75.
38. Block SL, Heikkinen T, Toback SL, Zheng W, Ambrose CS: The efficacy of live attenuated influenza vaccine against influenza-associated acute otitis media in children. Pediatr Infect Dis J 2011;30:203-7.
39. Belshe RB, Ambrose CS, Yi T: Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age. Vaccine 2008;26:10-6.
40. Hilleman MR: Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control. Vaccine 2002;20:3068-87. 799